Understand the research before the hype.
AEVLI separates approved medicines, investigational therapeutics and experimental compounds. Each profile shows what researchers are studying, what has actually been tested in humans and where uncertainty remains.
Research status varies dramatically. Tesamorelin and bremelanotide have specific FDA-approved uses; retatrutide is a late-stage investigational medicine; compounds such as BPC-157 and TB-500 remain unapproved research compounds. AEVLI does not provide sourcing, dosing, reconstitution or administration instructions.
BPC-157
A widely discussed experimental peptide with an extensive preclinical literature but very limited clinical evidence.
Read evidence profile →TB-500
A peptide fragment discussed alongside thymosin beta-4 research, but not equivalent to the full naturally occurring molecule.
Read evidence profile →CJC-1295
A long-acting GHRH analogue with early controlled human data showing sustained GH and IGF-1 signalling effects.
Read evidence profile →Ipamorelin
A ghrelin-receptor agonist and growth-hormone secretagogue with human pharmacology data but no approved consumer indication.
Read evidence profile →GHK-Cu
A copper-binding tripeptide studied in skin biology, extracellular-matrix signalling and tissue repair.
Read evidence profile →MOTS-c
A mitochondrial-derived peptide studied for metabolic signalling, exercise biology and cellular stress responses.
Read evidence profile →AOD-9604
A modified growth-hormone fragment studied historically in obesity and metabolic research.
Read evidence profile →KPV
A short alpha-MSH-derived tripeptide investigated mainly in laboratory and animal models of inflammation.
Read evidence profile →Epitalon
A tetrapeptide associated with ageing and telomere research, with intriguing hypotheses but limited high-quality clinical validation.
Read evidence profile →Semax & Selank
Two distinct peptides discussed in neurobiology and cognition research, with geographically concentrated clinical literature.
Read evidence profile →Retatrutide
A triple GIP, GLP-1 and glucagon receptor agonist in late-stage clinical development for obesity and metabolic disease.
Read evidence profile →Tesamorelin
A GHRH analogue with a genuine approved medical use and randomized human evidence—important context when it appears in broader peptide discussions.
Read evidence profile →Sermorelin
The 1–29 fragment of GHRH, with established human GH-stimulation pharmacology but a different evidence profile from modern approved GH-axis medicines.
Read evidence profile →PT-141 / Bremelanotide
A melanocortin receptor agonist where an internet “peptide” name overlaps with an FDA-approved prescription active ingredient.
Read evidence profile →Melanotan II
A synthetic melanocortin analogue widely discussed for tanning, but without an approved medical tanning indication and with significant evidence and product-quality concerns.
Read evidence profile →Thymosin alpha-1
A peptide with a substantial international clinical literature, but mixed results across indications and no basis for broad “immune boosting” claims.
Read evidence profile →LL-37
A human cathelicidin peptide with antimicrobial and wound-healing biology plus early controlled topical human trials.
Read evidence profile →DSIP
A historically studied “delta sleep-inducing peptide” whose name is more confident than the inconsistent human sleep evidence warrants.
Read evidence profile →Kisspeptin
A central regulator of human reproductive hormone signalling with a serious and expanding clinical research program.
Read evidence profile →Questions peptide communities keep asking.
Practical educational articles designed to help readers judge evidence and product claims without turning the site into an instruction manual.
Compare compounds without pretending they are equivalent.
Interesting research, without turning uncertainty into a promise.
Profiles distinguish mechanism from outcomes, preclinical findings from human evidence, and pharmaceutical approvals from similarly named research-market products.
Back to Learn